• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>MAP Pharmaceuticals

MAP Pharmaceuticals

  1. Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure

    Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.